Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE Extension: long-term open-label ralinepag in pulmonary arterial hypertension
NL-OMON49858Phase 3Not yet recruiting
- Sponsor
- United Therapeutics Corporation
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ralinepag in pulmonary arterial hypertension (PAH), sponsored by United Therapeutics Corporation. Primary endpoints: Long-term safety and tolerability of ralinepag, N-terminal pro b-type natriuretic peptide and 6 more. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
ralinepag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON49858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49858.